Le Lézard
Classified in: Health, Business
Subjects: DIV, ACC

DSM - Repurchase of Shares (10 - 14 September 2018)


HEERLEN, Netherlands, September 18, 2018 /PRNewswire/ --

Royal DSM, a global science-based company active in Nutrition, Health and Sustainable Living, has repurchased 94,032 of its own shares in the period from 10 September 2018 up to and including 14 September 2018 at an average price of ?88.38. This is in accordance with the repurchase, covering commitments under share based compensation plans and for stock dividends, announced on 13 August 2018. The consideration of this repurchase was ?8.3 million. 

     (Logo: https://mma.prnewswire.com/media/657851/DSM_Logo.jpg )

The total number of shares repurchased under this program to date is 699,443 shares for a total consideration of ?62.5 million.

For more detailed information see 'Daily transaction details 1.1m Share Repurchase Program announced 13 Aug 2018'.

DSM - Bright Science. Brighter Living.tm 

Royal DSM is a purpose-led global science-based company in Nutrition, Health and Sustainable Living. DSM is driving economic prosperity, environmental progress and social advances to create sustainable value for all stakeholders. DSM delivers innovative business solutions for human nutrition, animal nutrition, personal care and aroma, medical devices, green products and applications, and new mobility and connectivity. DSM and its associated companies deliver annual net sales of about ?10 billion with approximately 23,000 employees. The company is listed on Euronext Amsterdam. More information can be found at http://www.dsm.com.

Or find us on:

Facebook
Twitter
LinkedIn
YouTube

Forward-looking statements

This press release may contain forward-looking statements with respect to DSM's future (financial) performance and position. Such statements are based on current expectations, estimates and projections of DSM and information currently available to the company. DSM cautions readers that such statements involve certain risks and uncertainties that are difficult to predict and therefore it should be understood that many factors can cause actual performance and position to differ materially from these statements. DSM has no obligation to update the statements contained in this press release, unless required by law. The English language version of the press release is leading.

For more information:
DSM Media Relations
Lieke de Jong
tel. +31(0)45-578-2420        
e-mail [email protected]

DSM Investor Relations
Dave Huizing
tel. +31(0)45-578-2864
e-mail [email protected]

    PRN NLD


These press releases may also interest you

18 avr 2024
The 31st Canadian Cancer Society (CCS) Daffodil Ball, which took place this evening at Windsor Station in Montreal, raised $1,474,785 to fund innovative research projects and essential support programs for people living with cancer. The largest...

18 avr 2024
The report titled "Clinical Trials Matching Software Market by Functionality (Analytics & Reporting, Compliance Tracking, Data Management), Deployment (Cloud & Web Based, On-Premise), End-Use - Global Forecast 2024-2030" is now available on...

18 avr 2024
South Korea's biotechnology company Hyundai Bioscience (CEO Oh Sang-gi, www.hyundaibioscience.com) announced on April 15 that it would carry out global clinical tests aimed at treating all serotypes of Dengue virus infection....

18 avr 2024
The report titled "Progressive Familial Intrahepatic Cholestasis Treatment Market by Drug Type (Cholestyramine, Rifampicin, Ursodeoxycholic Acid), Distribution Channel (Hospital Pharmacies, Online Pharmacies, Retail Pharmacies), End-Users - Global...

18 avr 2024
RevolKa Ltd. (Norio Hamamatsu, President & CEO), a venture-backed biotech company providing a game-changing protein engineering technology platform and La Jolla Institute for Immunology (LJI) (Erica Saphire, President & CEO) agreed to start a...

18 avr 2024
Takeda (TSE:4502/NYSE:TAK) today announced that the U.S. Food and Drug Administration (FDA) has approved ENTYVIO® (vedolizumab) subcutaneous (SC) administration for maintenance therapy in adults with moderately to severely active Crohn's disease (CD)...



News published on and distributed by: